Xencor Inc

Financial Guidance Based on current operating plans, Xencor expects to end 2025 with between $555 million and $585 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2028.

SEC original ↗Xencor Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Financial Results for the Second Quarter Ended June 30, 2025 Cash, cash equivalents and marketable debt securities totaled $663.8 million as of June 30, 2025, compared to $706.7 million as of December 31, 2024.

SEC original ↗Xencor Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025

(basic and diluted) $ (0.41) $ (1.09) $ (1.07) $ (2.29) Weighted-average shares used in calculating (basic and diluted) 74,278,872 61,676,444 73,974,715 61,444,384 Other comprehensive income (loss) Net unrealized (loss) gain on marketable debt securities (97) (498) 921 (1,942) Comprehensive loss (30,922) (69,280) (78,536) (144,840) Less comprehensive loss attributable to the noncontrolling interest (1,445) (214) (2,121) Comprehensive loss attributable to Xencor, Inc.

SEC original ↗Xencor Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025

(basic and diluted) $ ( 0.29 ) $ ( 0.41 ) $ ( 1.99 ) $ ( 1.07 ) Weighted-average shares used in calculating net loss per share (basic and diluted) 75,859 74,279 75,555 73,975 Other comprehensive income (loss), net of tax: Net unrealized (loss) gain on marketable debt securities ( 899 ) ( 97 ) ( 2,448 ) 921 Comprehensive loss $ ( 22,628 ) $ ( 30,922 ) $ ( 153,093 ) $ ( 78,536 ) Less: comprehensive loss attributable to the noncontrolling interest ( 214 ) Comprehensive loss attributable to Xencor, Inc.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

The Company has evaluated the terms of both Ultomiris and Monjuvi Royalty Sale Agreements and concluded, in accordance with the relevant accounting guidance, that the Company accounted for both transactions as debt and the proceeds recorded as liabilities related to the sale of future royalties on its consolidated balance sheets.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

Xencor is focused on execution of our clinical studies, evaluating four wholly owned XmAb drug candidates in cancer and advanced autoimmune-driven diseases, said Bassil Dahiyat, Ph.

SEC original ↗Xencor Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025

, where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen s capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein design to biologics discovery.

SEC original ↗Xencor Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Any statements contained in this Quarterly Report on Form 10-Q except for historical information, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, may be deemed to be forward-looking statements.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

The Company is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

Fair Value Measurements The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results.

SEC original ↗Xencor Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics, the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, the risk of loss of key members of management and the risks, uncertainties and other factors described under the heading Risk Factors in Xencor's annual report on Form 10-K for the year ended December 31, 2024 as well as Xencor's subsequent filings with the Securities and Exchange Commission.

SEC original ↗Xencor Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Legal Proceedings 29 Item 1A.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

The forward-looking statements included herein are based on current expectations of the Company s management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond its control.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026

sales should be constrained to zero until the uncertainty was resolved.

SEC original ↗Xencor Inc — 10-Q Quarterly report10-QAug 5, 2026